GLG Topic: Pharmaceutical Industry
The Pharmaceutical Industry is the business sector typically encompassing the production and use of small molecule drugs derived from chemical sources. These substances are aimed at treating, curing, preventing, or recognizing disease.
Request a consultation
Leading Experts: Pharmaceutical Industry
 |
What is a GLG Leader? |
President and Chief Executive Officer
AciesHealth
Mark Capriani, MBA, is the President and Chief Executive Officer of AciesHealth, a specialty pharmaceutical company in Pennsylvania. He has over 15 years of experience in pharmaceutical industry including biotech, branded and multi source pharmaceuticals, consumer products, device, and wound and burn...
Nailesh BhattManaging Director
Proximare, Inc.
Nailesh Bhatt is the Managing Director of Proximare, Inc., a leading strategy consulting firm that exclusively serves the pharmaceutical industry with offices in New Jersey and India. In this role, Mr. Bhatt works with senior pharmaceutical executives to develop and implement growth strategies for R&D,...
President/Pharmaceutical Consultant
Dr. Kuldeepak Sharma
Kuldeepak Sharma, PhD, is a pharmaceutical consultant with twenty years of experience in research, clinical trials, business, patent and product development including: new process & technology development; clinical, project leadership; project planning; project management; patent research; managing...
Thomas SaundersPartner
SEYFARTH SHAW LLP
Thomas Saunders is a Partner at Seyfarth Shaw in Boston, Massachusetts, where he specializes in representing emerging medical technology, biotechnology/genetic engineering and pharmaceutical concerns, particularly as to patent prosecution, patent strategy, IP licensing matters and ANDA Paragraph IV...
Joseph Franciosa, MDOwner
Joseph A. Franciosa, MD, Consultant
Joseph Franciosa, MD, is an Independent Consultant to the pharmaceutical and medical devices industry and is also an Adjunct Professor of Medicine at Mt. Sinai School of Medicine and Weill Medical College of Cornell University in New York. He has pioneered in new treatments for heart failure and helped...
Study Groups: Pharmaceutical Industry(?)
GLG NewsSM
Analysis: Pharmaceutical Industry(?)
While pharmaceutical companies raised prices at a higher level than general inflation, implementing price controls is not the appropriate means to control drug spend. More effort needs to be placed on clinical trials and the demonstration of efficacy and value prior to a products release. ...
The cost of certain drugs is high -- but so are the regulatory costs and the financial risks of drug development. The process is overseen by the FDA, whose increasing risk-aversion continues to make drug development more expensive and uncertain.
The authors of this study obtained the data while representing plaintiffs and their lawyers.Surely they come from a biased viewpoint and perhaps more biased than groups of researchers who have performed a study may not have written all of a final manuscript but had the chance to review it. ...
The FDA at the end of it's investigation finds a firm in compliance or the firm gets a form 483, the pharmaceutical version of a speeding ticket.
1. PHRMA's R&D budget may have grown by a smaller percentage and positions have been cut due to mergers and acquisitions. 2. Biotech and non-PHRMA pharmaceutical company growth with increasing headcount , growing budgets and improved cost efficiencies may account for a portion of these...
Quick Facts about GLG
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms